• Sauson Soldozy, Anthony Skaff, Kamron Soldozy, Jennifer D Sokolowski, Pedro Norat, Kaan Yagmurlu, Khadijeh A Sharifi, Petr Tvrdik, Min S Park, KalaniM Yashar SMYSDepartment of Neurological Surgery, University of Virginia Health System, Charlottesville, Virginia.Deparment of Neuroscience, University of Virginia Health System, Charlottesville, Virginia., John A Jane, and Hasan R Syed.
• Department of Neurological Surgery, University of Virginia Health System, Charlottesville, Virginia.
• Neurosurgery. 2020 Nov 16; 87 (6): 1091-1097.

AbstractGlioma continues to be a challenging disease process, making up the most common tumor type within the pediatric population. While low-grade gliomas are typically amenable to surgical resection, higher grade gliomas often require additional radiotherapy in conjunction with adjuvant chemotherapy. Molecular profiling of these lesions has led to the development of various pharmacologic and immunologic agents, although these modalities are not without great systemic toxicity. In addition, the molecular biology of adult glioma and pediatric glioma has been shown to differ substantially, making the application of current chemotherapies dubious in children and adolescents. For this reason, therapies with high tumor specificity based on pediatric tumor cell biology that spare healthy tissue are needed. Oncolytic virotherapy serves to fill this niche, as evidenced by renewed interest in this domain of cancer therapy. Initially discovered by chance in the early 20th century, virotherapy has emerged as a viable treatment option. With promising results based on preclinical studies, the authors review several oncolytic viruses, with a focus on molecular mechanism and efficacy of these viruses in tumor cell lines and murine models. In addition, current phase I clinical trials evaluating oncolytic virotherapy in the treatment of pediatric glioma are summarized.Copyright © 2020 by the Congress of Neurological Surgeons.

16 keywords...

hide…